FBXO22 and lung carcinoma: Altogether, our findings demonstrate that our BACH1 signature successfully identified paeoniflorin as a novel BACH1 “inhibitor”, revealing its ability to promote BACH1 degradation via FBXO22 and to suppress lung cancer cell invasion in a FBXO22-BACH1 dependent manner.